Sources: Healthline
33 Similar findings were observed in a meta-analysis of 40 trials which concluded that GLP-1RAs were highly effective at lowering circulating glucose levels without causing hypoglycemia
Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care
#PharmaInsights #Retatrutide #Obesity #GLP1 #GIP #Glucagon #ObesityMedicine #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #PharmaceuticalMarketing To view or add a comment, sign in Hengrui and Kaileras late-stage success with an oral GLP-1 signals mounting competition in the already crowded obesity therapeutics race, but safety signals may dictate who truly leads this market
A low-friction quiz is still only the start of a medical review
The approach of the majority of nutritional interventions in cirrhosis is to supply at least 35 kcal/kg of body weight/day, with a daily recommended protein intake of 1.21.5 g/kg of body weight/day (sufficiently rich in branched-chain amino acids) to prevent or reverse muscle mass loss [460, 461, 463] (Table 10)
